
<document id="DBMI.pac185" origId="pac185">
	<sentence id="DBMI.pac185.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Interactions\n\nSimvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4."/>
	<sentence id="DBMI.pac185.s1" origId="s1" text="Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4."/>
	<sentence id="DBMI.pac185.s2" origId="s2" text="The risk of myopathy is increased by reducing the elimination of simvastatin."/>
	<sentence id="DBMI.pac185.s3" origId="s3" text="Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin."/>
	<sentence id="DBMI.pac185.s4" origId="s4" text="[See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]"/>
	<sentence id="DBMI.pac185.s5" origId="s5" text="Itraconazole, ketoconazole, and other antifungal azoles\n\nMacrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin\n\nHIV protease inhibitors\n\nAntidepressant nefazodone\n\nGrapefruit juice in large quantities (&gt;1 quart daily)\n\nConcomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk."/>
	<sentence id="DBMI.pac185.s6" origId="s6" text="If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment."/>
	<sentence id="DBMI.pac185.s7" origId="s7" text="7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone\n\nThe risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day)."/>
	<sentence id="DBMI.pac185.s8" origId="s8" text="[see Warnings and Precautions (5.1)]."/>
	<sentence id="DBMI.pac185.s9" origId="s9" text="7.3 Cyclosporine or Danazol\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac185.s10" origId="s10" text="7.4 Amiodarone or Verapamil\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)]."/>
	<sentence id="DBMI.pac185.s11" origId="s11" text="7.5 Digoxin\n\nIn one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.">
		<entity charOffset="2157-2169" id="DBMI.pac185.s11.e0" origId="s11.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="2144-2152" id="DBMI.pac185.s11.e1" origId="s11.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac185.s11.e0" e2="DBMI.pac185.s11.e1" id="DBMI.pac185.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac185.s11.e1" e2="DBMI.pac185.s11.e0" id="DBMI.pac185.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac185.s12" origId="s12" text="Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac185.s13" origId="s13" text="7.6 Coumarin Anticoagulants\n\nIn two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively."/>
	<sentence id="DBMI.pac185.s14" origId="s14" text="With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly."/>
	<sentence id="DBMI.pac185.s15" origId="s15" text="In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs."/>
	<sentence id="DBMI.pac185.s16" origId="s16" text="Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants."/>
	<sentence id="DBMI.pac185.s17" origId="s17" text="If the dose of simvastatin is changed or discontinued, the same procedure should be repeated."/>
	<sentence id="DBMI.pac185.s18" origId="s18" text="Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants."/>
	<sentencespan id="DBMI.pac185.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Interactions\n\nSimvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. The risk of myopathy is increased by reducing the elimination of simvastatin."/>
	<sentencespan id="DBMI.pac185.sp1" origId="sp1" text="Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Itraconazole, ketoconazole, and other antifungal azoles\n\nMacrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin\n\nHIV protease inhibitors\n\nAntidepressant nefazodone\n\nGrapefruit juice in large quantities (&gt;1 quart daily)\n\nConcomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk."/>
	<sentencespan id="DBMI.pac185.sp2" origId="sp2" text="If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment. 7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone\n\nThe risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day). [see Warnings and Precautions (5.1)]."/>
	<sentencespan id="DBMI.pac185.sp3" origId="sp3" text="7.3 Cyclosporine or Danazol\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 7.4 Amiodarone or Verapamil\n\nThe risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)]. 7.5 Digoxin\n\nIn one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.">
		<entity charOffset="2157-2169" id="DBMI.pac185.sp3.e0" origId="sp3.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="2144-2152" id="DBMI.pac185.sp3.e1" origId="sp3.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac185.sp3.e0" e2="DBMI.pac185.sp3.e1" id="DBMI.pac185.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac185.sp3.e1" e2="DBMI.pac185.sp3.e0" id="DBMI.pac185.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac185.sp4" origId="sp4" text="Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)]. 7.6 Coumarin Anticoagulants\n\nIn two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly."/>
	<sentencespan id="DBMI.pac185.sp5" origId="sp5" text="In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated."/>
	<sentencespan id="DBMI.pac185.sp6" origId="sp6" text="Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants."/>
</document>
